Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.

Journal of neuro-oncology - 1 May 2023

Eichkorn Tanja, Lischalk Jonathan W, Hörner-Rieber Juliane, Deng Maximilian, Meixner Eva, Krämer Anna, Hoegen Philipp, Sandrini Elisabetta, Regnery Sebastian, Held Thomas, Harrabi Semi, Jungk Christine, Herfarth Klaus, Debus Jürgen, König Laila

Abstract excerpt

PURPOSE: Proton beam radiotherapy (PRT) has been demonstrated to improve neurocognitive sequelae particularly. Nevertheless, following PRT, increased rates of radiation-induced contrast enhancements (RICE) are feared. How safe and effective is PRT for IDH-mutated glioma WHO grade 2 and 3? METHODS: We analyzed 194 patients diagnosed with IDH-mutated WHO grade 2 (n = 128) and WHO grade 3 (n = 66) glioma who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Protons

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 36598613
DOI: 10.1007/s11060-022-04217-y
PMCID: PMC10227167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.PMID 36598613Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

Current Considerations in the Treatment of Grade 3 Gliomas.Semantic proximity Read ↗

Clinical Characteristics, Treatment Outcomes, And Genetic Alterations of Radiation-Induced GliomasSemantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

Assessment of Therapeutic Outcome and Role of Reirradiation in Patients With Radiation-induced GliomaSemantic proximity Read ↗

Survival, late toxicity and ability to return to work after proton radiotherapy for low grade gliomasSemantic proximity Read ↗

Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.Semantic proximity Read ↗

IDH1R132H mutation increases radiotherapy efficacy and a 4-gene radiotherapy-related signature of WHO grade 4 gliomas.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma.Semantic proximity Read ↗

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.Semantic proximity Read ↗

Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO grade 2 and 3 gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.